Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The group lawsuit representing people harmed by Mounjaro and other GLP-1 drugs has grown by 486 cases between August and September of 2025
The nursing home industry instinctively claims that the cause is Medicaid rates that are low, too low even to cover nursing home costs (See our joint letter, below)
The results lasted about 4 months
What Biosimilar Launch Timing Actually Depends On in a CIP-Heavy Patent Landscape Biosimilar launch timing in a CIP-heavy patent landscape is determined by three factors operating in sequence: the settlement negotiations between the innovator and the biosimilar developer, the results of any litigation on patents the parties cannot resolve by agreement, and the regulatory exclusivity periods 12 years for reference biologics under the BPCIA that run independently of patent status
.webp)
US$ 21.66
US$ 21.05
US$ 28.31
US$ 22.24
US$ 25.46
